About Parithera
Parithera enables accurate treatment decision guidance & monitoring from one simple blood draw
An alternative to tissue biopsy is to study cells which detach from the solid tumors and find access to the blood stream. The so-called circulating tumor cells (CTCs) are retrieved via Liquid Biopsy.
Parithera ExTrace enables clinicians to monitor treatment response and choose the best therapy based on single cell RNA (scRNA) sequencing data.
Parithera’s innovative approach is based on two inventions in the domain of CTC isolation and sequencing preparation.
- Founding: 2021
- Focus : Manufacturer
- Employees: 1-10
- Industry : Diagnostics
Here you will find Parithera SA
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
